Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification

K. Yamato, N. Egawa, S. Endo, K. Ui-Tei, T. Yamada, K. Saigo, I. Hyodo, T. Kiyono, I. Nakagawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although efforts have been made to develop new drugs for infectious and neoplastic diseases utilizing synthetic small interfering RNA(siRNAs), those intrinsically have undesirable effects, including silencing of unintended genes (off-target effect) and nonspecific cytotoxicity. Off-target effects can be avoided by DNA substitution in the guide strand (GS) seed region of nucleotide positions 1-8 and its complementary part of the passenger strand plus the 3′ overhang, which is designated as a double-strand RNA-DNA chimera (dsRDC). In this study, we found that the specificity of potent siRNAs targeting human papillomavirus 16 (HPV16) E6 and E7 oncogenes, which we previously reported, could be enhanced by short dsRDC modification (first six nucleotides from the 5′ end of the GS and its complementary nucleotides of the passenger strand). Such dsRDC modification reduced nonspecific cytotoxicity in two of three siRNAs (497 and 752), although not in the other (573), which correlated with their off-target effects. In addition, silencing activity was marginally impaired in two dsRDCs (497 and 573) and moderately in one (752). Finally, dsRDC-497 induced E6E7-specific growth suppression of cervical cancer cells as well as E6E7-immortalized human keratinocytes. Our results show that dsRDC modification enhances the specificity of E6E7 siRNA, which is required for use in in vivo settings.

Original languageEnglish
Pages (from-to)587-597
Number of pages11
JournalCancer Gene Therapy
Volume18
Issue number8
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Human papillomavirus 16
Small Interfering RNA
RNA
DNA
Nucleotides
Gene Silencing
Keratinocytes
Oncogenes
Uterine Cervical Neoplasms
Communicable Diseases
Seeds
Growth
Pharmaceutical Preparations

Keywords

  • cervical cancer
  • HPV16
  • off-target effect
  • siRNA therapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Yamato, K., Egawa, N., Endo, S., Ui-Tei, K., Yamada, T., Saigo, K., ... Nakagawa, I. (2011). Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Therapy, 18(8), 587-597. https://doi.org/10.1038/cgt.2011.28

Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. / Yamato, K.; Egawa, N.; Endo, S.; Ui-Tei, K.; Yamada, T.; Saigo, K.; Hyodo, I.; Kiyono, T.; Nakagawa, I.

In: Cancer Gene Therapy, Vol. 18, No. 8, 08.2011, p. 587-597.

Research output: Contribution to journalArticle

Yamato, K, Egawa, N, Endo, S, Ui-Tei, K, Yamada, T, Saigo, K, Hyodo, I, Kiyono, T & Nakagawa, I 2011, 'Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification', Cancer Gene Therapy, vol. 18, no. 8, pp. 587-597. https://doi.org/10.1038/cgt.2011.28
Yamato K, Egawa N, Endo S, Ui-Tei K, Yamada T, Saigo K et al. Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Therapy. 2011 Aug;18(8):587-597. https://doi.org/10.1038/cgt.2011.28
Yamato, K. ; Egawa, N. ; Endo, S. ; Ui-Tei, K. ; Yamada, T. ; Saigo, K. ; Hyodo, I. ; Kiyono, T. ; Nakagawa, I. / Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. In: Cancer Gene Therapy. 2011 ; Vol. 18, No. 8. pp. 587-597.
@article{a96cee88302c4de8a458be50bd38dc7d,
title = "Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification",
abstract = "Although efforts have been made to develop new drugs for infectious and neoplastic diseases utilizing synthetic small interfering RNA(siRNAs), those intrinsically have undesirable effects, including silencing of unintended genes (off-target effect) and nonspecific cytotoxicity. Off-target effects can be avoided by DNA substitution in the guide strand (GS) seed region of nucleotide positions 1-8 and its complementary part of the passenger strand plus the 3′ overhang, which is designated as a double-strand RNA-DNA chimera (dsRDC). In this study, we found that the specificity of potent siRNAs targeting human papillomavirus 16 (HPV16) E6 and E7 oncogenes, which we previously reported, could be enhanced by short dsRDC modification (first six nucleotides from the 5′ end of the GS and its complementary nucleotides of the passenger strand). Such dsRDC modification reduced nonspecific cytotoxicity in two of three siRNAs (497 and 752), although not in the other (573), which correlated with their off-target effects. In addition, silencing activity was marginally impaired in two dsRDCs (497 and 573) and moderately in one (752). Finally, dsRDC-497 induced E6E7-specific growth suppression of cervical cancer cells as well as E6E7-immortalized human keratinocytes. Our results show that dsRDC modification enhances the specificity of E6E7 siRNA, which is required for use in in vivo settings.",
keywords = "cervical cancer, HPV16, off-target effect, siRNA therapy",
author = "K. Yamato and N. Egawa and S. Endo and K. Ui-Tei and T. Yamada and K. Saigo and I. Hyodo and T. Kiyono and I. Nakagawa",
year = "2011",
month = "8",
doi = "10.1038/cgt.2011.28",
language = "English",
volume = "18",
pages = "587--597",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification

AU - Yamato, K.

AU - Egawa, N.

AU - Endo, S.

AU - Ui-Tei, K.

AU - Yamada, T.

AU - Saigo, K.

AU - Hyodo, I.

AU - Kiyono, T.

AU - Nakagawa, I.

PY - 2011/8

Y1 - 2011/8

N2 - Although efforts have been made to develop new drugs for infectious and neoplastic diseases utilizing synthetic small interfering RNA(siRNAs), those intrinsically have undesirable effects, including silencing of unintended genes (off-target effect) and nonspecific cytotoxicity. Off-target effects can be avoided by DNA substitution in the guide strand (GS) seed region of nucleotide positions 1-8 and its complementary part of the passenger strand plus the 3′ overhang, which is designated as a double-strand RNA-DNA chimera (dsRDC). In this study, we found that the specificity of potent siRNAs targeting human papillomavirus 16 (HPV16) E6 and E7 oncogenes, which we previously reported, could be enhanced by short dsRDC modification (first six nucleotides from the 5′ end of the GS and its complementary nucleotides of the passenger strand). Such dsRDC modification reduced nonspecific cytotoxicity in two of three siRNAs (497 and 752), although not in the other (573), which correlated with their off-target effects. In addition, silencing activity was marginally impaired in two dsRDCs (497 and 573) and moderately in one (752). Finally, dsRDC-497 induced E6E7-specific growth suppression of cervical cancer cells as well as E6E7-immortalized human keratinocytes. Our results show that dsRDC modification enhances the specificity of E6E7 siRNA, which is required for use in in vivo settings.

AB - Although efforts have been made to develop new drugs for infectious and neoplastic diseases utilizing synthetic small interfering RNA(siRNAs), those intrinsically have undesirable effects, including silencing of unintended genes (off-target effect) and nonspecific cytotoxicity. Off-target effects can be avoided by DNA substitution in the guide strand (GS) seed region of nucleotide positions 1-8 and its complementary part of the passenger strand plus the 3′ overhang, which is designated as a double-strand RNA-DNA chimera (dsRDC). In this study, we found that the specificity of potent siRNAs targeting human papillomavirus 16 (HPV16) E6 and E7 oncogenes, which we previously reported, could be enhanced by short dsRDC modification (first six nucleotides from the 5′ end of the GS and its complementary nucleotides of the passenger strand). Such dsRDC modification reduced nonspecific cytotoxicity in two of three siRNAs (497 and 752), although not in the other (573), which correlated with their off-target effects. In addition, silencing activity was marginally impaired in two dsRDCs (497 and 573) and moderately in one (752). Finally, dsRDC-497 induced E6E7-specific growth suppression of cervical cancer cells as well as E6E7-immortalized human keratinocytes. Our results show that dsRDC modification enhances the specificity of E6E7 siRNA, which is required for use in in vivo settings.

KW - cervical cancer

KW - HPV16

KW - off-target effect

KW - siRNA therapy

UR - http://www.scopus.com/inward/record.url?scp=79960562542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960562542&partnerID=8YFLogxK

U2 - 10.1038/cgt.2011.28

DO - 10.1038/cgt.2011.28

M3 - Article

C2 - 21660064

AN - SCOPUS:79960562542

VL - 18

SP - 587

EP - 597

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -